149976-78-3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 5866-97-7 2,6-dichloro-3-nitrobenzaldehyde 

Downstream Products

• 160647-05-2 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine 
• 206882-37-3 5-(2,6-dichloro-3-nitrobenzyloxy)isoquinoline 
• 206883-01-4 5-(3-amino-2,6-dichlorobenzyloxy)isoquinoline 
• 206882-50-0 5-(3-acetamido-2,6-dichlorobenzyloxy)isoquinoline 
• 206883-18-3 5-(5-amino-2-chloro-6-methylthio)benzyloxyisoquinoline 
• 206883-20-7 5-(3-amino-2,6-bis-methylthio-benzyloxy)isoquinoline 
• 206883-19-4 5-(3-amino-2-chloro-6-methylthio)benzyloxyisoquinoline 
• 206883-97-8 5-(2-chloro-6-methylthio-5-nitrobenzyloxy)isoquinoline 
• 206883-98-9 5-(2-chloro-6-methylthio-3-nitrobenzyloxy)isoquinoline 
• 206883-99-0 5-(2,6-bis-methylthio-3-nitrobenzyloxy)isoquinoline 
• 258842-80-7 5-{(2,6-dichloro-3-chloroacetylamino)benzyloxy}isoquinoline 
• 206883-69-4 5-(3-bismethanesulfonylamino-2,6-dichlorobenzyloxy)isoquinoline 
• 206884-32-4 5-(3-acetylmethylacetamido-2,6-dichlorobenzyloxy)isoquinoline 
• 206883-95-6 5-(2-chloro-6-ethoxycarbonylmethylthio-5-nitrobenzyloxy)isoquinoline 

Relevant academic research and scientific papers

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework

A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-α]pyridine derivative 2. The unique screening lead (2) was discovered b

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation

In recent articles we reported the identification of a series of 8- [[2,6-dichloro-3-[N-methyl-N-[(E)- (substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2- a]pyridines as the first orally active non-peptide bradykinin (BK) B2 rece

IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE

The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.